Back to Authors

Lieber, Michael M.

A5113874291 | I1285764155

Mayo Clinic

Merck & Co., Inc., Rahway, NJ, USA (United States)

Citations 92

Transitional Cell Carcinoma of the Upper Urinary Tract: Evaluation of Prognostic Factors by Histopathology and Flow Cytometric Analysis

Journal of Urology | June 29, 2017 | Volume: 145 | Issue: 6 | Pages: 1159-1163

10.1016/s0022-5347(17)38562-2 | PMID 2033684

Editorial Comments

Journal of Urology | June 29, 2017 | Volume: 145 | Issue: 6 | Pages: 1196-1196

10.1016/s0022-5347(17)38573-7

Nuclear Deoxyribonucleic Acid Ploidy and Serum Prostate Specific Antigen in Operable Prostatic Adenocarcinoma

Journal of Urology | June 29, 2017 | Volume: 144 | Issue: 2 Part 1 | Pages: 303-306

10.1016/s0022-5347(17)39437-5 | PMID 1695690

Editorial Comment

Journal of Urology | June 29, 2017 | Volume: 142 | Issue: 2 Part 1 | Pages: 376-376

10.1016/s0022-5347(17)38766-9

The Japanese Journal of Urology | April 6, 2017 | Volume: 89 | Issue: 2 | Pages: 267

10.5980/jpnjurol.89.267_2

The Japanese Journal of Urology | April 6, 2017 | Volume: 87 | Issue: 2 | Pages: 283

10.5980/jpnjurol.87.283_1

Factors Associated with Adherence to an End-of-Study Biopsy: Lessons from the Prostate Cancer Prevention Trial (SWOG-Coordinated Intergroup Study S9217)

Cancer Epidemiology, Biomarkers & Prevention | July 16, 2014 | Volume: 23 | Issue: 8 | Pages: 1638-1648

10.1158/1055-9965.epi-14-0202 | PMID 25028457

Abstract Background: The Prostate Cancer Prevention Trial (PCPT) was a 7-year randomized, double-blind, placebo-controlled trial of the efficacy of finasteride for the prevention of prostate cancer with a primary outcome of histologically determined prevalence of prostate cancer at the end of 7 years. Methods: A systematic modeling process using logistic regression identified factors available at year 6 that are associated with end-of-study (EOS) biopsy adherence at year 7, stratified by whether participants were ever prompted for a prostate biopsy by year 6. Final models were evaluated for discrimination. At year 6, 13,590 men were available for analysis. Results: Participants were more likely to have the EOS biopsy if they were adherent to study visit schedules and procedures and/or were in good health (P < 0.01). Participants at larger sites and/or sites that received retention and adherence grants were also more likely to have the EOS biopsy (P < 0.05). Conclusions: Our results show good adherence to study requirements 1 year before the EOS biopsy was associated with greater odds that a participant would comply with the invasive EOS requirement. Impact: Monitoring adherence behaviors may identify participants at risk of nonadherence to more demanding study end points. Such information could help frame adherence intervention strategies in future trials. Cancer Epidemiol Biomarkers Prev; 23(8); 1638–48. ©2014 AACR.
Distribution and Associations of [−2]Proenzyme-Prostate Specific Antigen in Community Dwelling Black and White Men

Journal of Urology | November 17, 2011 | Volume: 187 | Issue: 1 | Pages: 92-96

10.1016/j.juro.2011.09.060 | PMID 22093189

Benign Prostate Specific Antigen Distribution and Associations With Urological Outcomes in Community Dwelling Black and White Men

Journal of Urology | November 17, 2011 | Volume: 187 | Issue: 1 | Pages: 87-91

10.1016/j.juro.2011.09.061 | PMID 22093190

1722 ASSOCIATIONS BETWEEN MODEST WEIGHT LOSS AND ONSET AND PROGRESSION OF LOWER URINARY TRACT SYMPTOMS

Journal of Urology | May 20, 2011 | Volume: 185 | Issue: 4S | Pages: No page available

10.1016/j.juro.2011.02.1993